

## References

S-97

1. Wolff JM, Mason M. Drivers for change in the management of prostate cancer - guidelines and new treatment techniques. *BJU Int*. 2012;109 Suppl 6:33-41.
2. Qi J, Yu YJ, Huang T, et al. Comparison of the predictive value between ultrasonography and urodynamics for the efficacy of transurethral resection of prostate in benign prostatic hyperplasia patients. *Chin Med J (Engl)*. 2012;125(9):1536-41.
3. InterQual® Level of Care 2014. Acute Care Adult. McKesson Health Solutions, Inc.
4. Shrivastava A, Gupta V. Various treatment options for benign prostatic hyperplasia: A current update. *Journal of Mid-Life Health*. 2012;3(1):10-19.
5. McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association Guideline: Management of benign prostatic hyperplasia (BPH). 2014.
6. Thiruchelvam N. Surgical therapy for benign prostatic hypertrophy/bladder outflow obstruction. *Indian J Urol*. 2014; 30(2): 202–207.
7. National Cancer Institute at the National Institutes of Health: Prostate Cancer Treatment – Treatment option overview for prostate cancer.
8. Hale Z, Miyake M, Palacios D A, et al. Focal cryosurgical ablation of the prostate: a single institute's perspective. *BioCentral Urology*. 2013;13:2.
9. Wang MQ, Guo LP, Zhang GD et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population. *BMC Urol*. 2015;(15)1:33.
10. Carnevale FC, Antunes AA, Motta-Leal-Filho JMD, et al. Review of current outcomes of prostate artery embolization to treat patients with lower urinary tract symptoms due to benign prostatic hyperplasia. *UroToday International Journal*. 2012;5.
11. Crouzet S, Chapelon JY, Rouvière O, et al. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: Oncologic outcomes and morbidity in 1002 patients. *European Urology* 2014; (65)5:907-914.
12. Oto A, Sethi I, Karcsmar G et al. MR image-guided focal laser ablation for prostate cancer: Phase I Trial. *Radiology* 2013;(267)3:932-34.
13. Wenger H, Yousef A, Oto A et al. Laser Ablation as focal therapy for prostate cancer. *Curr Opin Urol*. 2014 ;24(3):236-40.
14. Roehrborn CG, Gange SN, Shore ND et al. Durability of the prostatic urethral lift: 2-year results of the L.I.F.T. study. *Urology Practice* 2015;2:1-7.
15. Shore N, Freedman S, Gance S et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. *The Canadian Journal of Urology* 2014;21(1):7094-7101.
16. Cantwell AL, Bogache WK, Richardson SF et al. Multi-center prospective crossover study of the prostatic urethral lift for the treatment of LUTS secondary to BPH. *BJU Int* 2014;113(4):615-22.

17. McVary KT, Gange SN, Shore ND et al. Treatment of LUTS secondary to BPH while preserving sexual function: Randomized controlled study of prostatic urethral lift. *J Sex Med.* 2014;11(1):279-87.
18. Roehrborn CG, Gange SN, Shore ND et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. *J Urol.* 2013;190(6):2161-7.
19. McNicholas TA, Woo HH, Chin PT et al. Minimally invasive prostatic urethral list: surgical technique and multinational experience. *Eur Urol.* 2013;64(2):292-9.
20. Shore N. A review of the prostatic urethral lift for lower urinary tract symptoms: Symptom relief, flow improvement, and preservation of sexual function in men with benign prostatic hyperplasia. *Curr Bladder Dysfunct Rep* 2015.
21. Sonsken J, Barber N, Speakman M et al. Prospective, randomized, multi-national study of the prostatic urethral Lift (PUL) vs transurethral resection of the prostate (TURP): 12 Month Results of the BPH6 Study.
22. National Institute for Clinical Excellence [NICE] United Kingdom: Interventional procedure guidance guideline for insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2014.
23. Peyton CC, Badlani GH. The management of prostatic obstruction with urethral stents. *Can J Urol.* 2015;75-81.
24. Aoun F, Marcelis Q, Roumeguere T. Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: Technology update. *Research and Reports in Urology.* 2015;125-136.
25. Alkhorayef M, Mahmoud MZ, Alzimami KS, et al. High-intensity focused ultrasound (HIFU) in localized prostate cancer treatment. *Pol J Radiol.* 2015;131-141.
26. Robertson C, Sliwinski A, Wallen E, et al. United States experience with primary HIFU therapy for patients with low-risk prostate cancer: results of the Enlight trial. *J of Ther US.* 2014;12-16.
27. Li Q, Wang MQ, Zhang GD, Yuan K. Prostatic arterial embolization with small sized particles for the treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia: Preliminary results. *Chin Med J.* 2015;2072-2077.
28. Tholomier C, Valdivieso R, Hueber P, et al. Photoselective laser ablation of the prostate: A review of the current 2015 tissue ablation options. *Can J Urol.* 2015;45-52.
29. Lepor H, Llukani E, Sperling D, et al. Complications, recovery, and early functional outcomes and oncologic control following in-bore focal laser ablation of prostate cancer. *Eur Assoc Urol.* 2015;924-926.
30. Lee T, Mendhiratta N, Sperling D, et al. Focal laser ablation for localized prostate cancer: Principles, clinical trials, and our initial experience. *Rev Urol.* 2014;55-66.
31. Perera M, Roberts MJ, Doi SAR, et al. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: A systematic review and meta-analysis. *Eur Assoc Urol.* 2014;714-715.
32. Doyle C. Study: BPH procedure's benefits sustained at 3 years. *Urology Times.* 2015;1.

33. American Urology Association. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). *AUA*. 2010;1-27.